Paradigm Spine selected the PharmaPros automated trial management solution, Dataflow Manager. The software tracks the status of a trial, including any available information, including lab data, case report forms, images, and randomization. “After careful evaluation of our internal needs and capacity, along with a thorough analysis of available external options, we found Dataflow Manager to provide a level of in-stream visibility unmatched by other solutions. We have a philosophy of being data-driven, and Dataflow Manager allows us to stay true to that vision,” said Marc Viscogliosi, CEO of Paradigm Spine. Here’s an earlier story from our site on PharmaPros.

Protein’eXpert changed its name to PX’Therapeutics. “Our new corporate identity better reflects our expanded mission to provide our clients access to a high technical expertise, a flexible and efficient platform, and a comprehensive approach to their therapeutic projects development,” explained Tristan Rousselle, CEO.

Adlib Software and Good Products announced a collaboration to facilitate the processing of regulatory documents. Peter Duff, president and CEO of Adlib Software, said: “The integration of g-docs and Express Server accelerates regulatory submissions and enables organizations to manage documents in a compliant way across the whole life cycle, from creation to regulatory submission.” Here’s a release.

Bio-Quant, a San Diego based CRO, has expanded its animal diagnostic services division to cover all nine major species used in contract research. Bassam Damaj, CEO of Bio-Quant, said: “Animal welfare is of great importance, and Bio-Quant is very pleased to announce the expansion of its Research Animal Diagnostic Services.” Here’s the release.

Clinsys Clinical Research launched its Passionately Pink for the Cure campaign, a company-wide breast cancer awareness and fund-raising program supporting Susan G. Komen for the Cure. The company will match all donations received through the yearlong campaign. “For more than 15 years, Clinsys has dedicated its clinical trial expertise to finding cures for all forms of cancer,” said David Williams, CEO of Clinsys. “We are proud to take our commitment to research one step further.” Here’s the release.

Two contract research firms, Novalyst Discovery and AliX, have agreed to merge. They have formed NovAliX, a multidisciplinary company providing flexible outsourcing solutions for drug discovery and development. The combined company will represent a major provider able to deliver comprehensive services from gene to preclinical drug candidates and especially offering alternative fragment–based drug discovery approaches. “There was a natural synergy between the two companies whose expertise in chemistry and structural biology brings a valuable set of skills for our drug discovery program,” claimed Stephan Jenn, president. This is the new NovAliX website.

We’ve tried to keep presidential politics off this site, just because we can’t be sure how many of our readers are taking anti-nausea medications. But this news clip may be worth a look.

Synairgen picked Exco InTouch’s electronic patient reported outcomes (ePRO) solution. The Exco short message system (SMS) technology allows patients to complete diary questionnaires at pre-specified times via a series of messages that enable Synairgen’s patients to easily record and transmit asthma-related data. “Symptom diary cards are notoriously unreliable; we are attracted to this simple method for collecting asthma symptom scores on a daily basis,” said Richard Marsden of Synairgen. ClinPage wrote this about Exco.

Have a news release? Send it to .